Patents Issued in November 14, 2017
-
Patent number: 9814703Abstract: Methods for treating cancer by activation of the Bmp pathway are disclosed. In particular, the invention relates to methods of treating cancer using agents that activate BMP signaling, e.g., FK506 (tacrolimus), to treat a subject for cancer.Type: GrantFiled: November 13, 2014Date of Patent: November 14, 2017Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Philip A. Beachy, Kunyoo Shin
-
Patent number: 9814704Abstract: Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. The compounds include substituted pyrrolo[2,3-b]pyridines having Formula IX Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.Type: GrantFiled: June 3, 2016Date of Patent: November 14, 2017Assignee: The University of RochesterInventors: Harris A. Gelbard, Stephen Dewhurst, Val S. Goodfellow, Colin J. Loweth, Torsten Wiemann
-
Patent number: 9814705Abstract: An intranasal spray device contains a composition for the intranasal delivery of fentanyl or a pharmaceutically acceptable salt thereof to an animal includes an aqueous solution of fentanyl or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable additive selected from (i) a pectin and (ii) a poloxamer and chitosan or a salt or derivative thereof; provided that when the composition comprises a pectin it is substantially free of divalent metal ions; and which, in comparison to a simple aqueous solution of fentanyl administered intranasally at the same dose, provides a peak plasma concentration of fentanyl (Cmax) that is from 10 to 80% of that achieved using a simple aqueous solution of fentanyl administered intranasally at an identical fentanyl dose. A method for treating or managing pain by intranasally administering the composition is also disclosed.Type: GrantFiled: June 23, 2015Date of Patent: November 14, 2017Assignee: Depomed, Inc.Inventors: Peter James Watts, Jonathan David Castile, William Columbus Ian Lafferty, Alan Smith
-
Patent number: 9814706Abstract: This invention relates to a new salt of Pridopidine, a drug substance currently in development for the treatment of Huntington's disease. More specifically the invention provides the pharmaceutically acceptable hydrobromide salt, pharmaceutical compositions comprising this salt, and uses of this salt as a drug substance.Type: GrantFiled: February 4, 2015Date of Patent: November 14, 2017Assignee: TEVA PHARMACEUTICALS INTERNATIONAL GMBHInventors: Anne Zimmermann, Brian Frøstrup
-
Patent number: 9814707Abstract: The present invention is directed to provide cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species. To this end, provided are cancer stem cell proliferation inhibitors and inducers of intracellular accumulation of reactive oxygen species in a cancer stem cell each containing pimozide or sertindole as an active ingredient.Type: GrantFiled: January 23, 2015Date of Patent: November 14, 2017Assignee: Keio UniversityInventors: Hideyuki Saya, Osamu Nagano, Shogo Okazaki
-
Patent number: 9814708Abstract: The present invention relates to new pharmaceutical compositions comprising benzoquinoline compounds, and methods to inhibit vesicular monoamine transporter 2 (VMAT2) activity in a subject for the treatment of chronic hyperkinetic movement disorders.Type: GrantFiled: February 16, 2016Date of Patent: November 14, 2017Assignee: Auspex Pharmaceuticals, Inc.Inventors: Andreas Sommer, Chengzhi Zhang, John Carter, John Arthur, Margaret Bradbury, Thomas Gant, Manouchehr Shahbaz
-
Patent number: 9814709Abstract: The present invention provides a Bruton's tyrosine kinase inhibitor, which is a compound represented by formula (I) or a pharmaceutically acceptable salt, solvate, ester, acid, metabolite or prodrug thereof. The present invention also provides a pharmaceutical composition comprising the compound. The present invention also provides a method and use of using the Bruton's tyrosine kinase inhibitor to inhibit the tyrosine kinase activity or treat diseases, disorders or symptoms benefiting from the inhibition of the Bruton's tyrosine kinase (Btk) activity.Type: GrantFiled: January 27, 2015Date of Patent: November 14, 2017Assignees: HEFEI INSTITUTES OF PHYSICAL SCIENCE, CHINESE ACADEMY OF SCIENCES, ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD.Inventors: Qingsong Liu, Jing Liu, Yongfei Chen, Hong Wu, Aoli Wang, Beilei Wang, Chen Hu, Wenchao Wang, Cheng Chen
-
Patent number: 9814710Abstract: The present invention relates to prolonged release pharmaceutical dosage forms comprising hydromorphone or a pharmaceutically acceptable salt thereof and naloxone or a pharmaceutically acceptable salt thereof for use in the treatment of pain.Type: GrantFiled: November 13, 2014Date of Patent: November 14, 2017Assignee: Euro-Celtique S.A.Inventors: Helen Kathleen Danagher, Hassan Mohammad, Malcolm Walden, Geoffrey Gerard Hayes, Jonathon Oliver Whitehouse, Thinnayam Naganathan Krishnamurthy, Ricardo Alberto Vargas Rincon
-
Patent number: 9814711Abstract: The present invention relates to a monolayer tablet for use in the treatment of tuberculosis comprising a mixture of: —granules comprising isoniazid, pyrazinamide, ethambutol or a pharmaceutically acceptable salt thereof and at least one granulation binder, —rifampicin in powder form, —extragranular excipients, wherein all of the granules have a particle size that is less than 0.599 mm, preferably less than 0.5 mm, more preferably less than 0.422 mm, and to its process of preparation.Type: GrantFiled: July 22, 2014Date of Patent: November 14, 2017Assignee: SANOFIInventors: Kumar Amith, Madavan Bindu, Prasad Kum, Khullar Praveen
-
Patent number: 9814712Abstract: (S)-pirlindole or its pharmaceutically acceptable salts, as well as pharmaceutical compositions comprising the same for use in the therapeutic treatment and prevention of pain.Type: GrantFiled: May 9, 2014Date of Patent: November 14, 2017Assignee: TECNIMEDE SOCIEDADE TECNICO-MEDICINAL S.A.Inventors: Augusto Eugenio Pardal Filipe, Pedro Filipe Eufrasio Pedroso, Susana Marques Almeida Pecorelli, Carlos Alberto Eufrasio Casimiro Caixado, Ana Sofia da Conceicao Lopes, Joao Carlos Damil
-
Patent number: 9814713Abstract: Provided herein are formulations, processes, solid forms and methods of use relating to 2 -(tert-butylamino)-4-((1R,3R,4R)-3-hydroxy-4-methylcyclohexylamino)-pyrimidine-5-carboxamide.Type: GrantFiled: May 12, 2016Date of Patent: November 14, 2017Assignee: Signal Pharmaceuticals, LLCInventors: Hon-Wah Man, Jean Xu, Marie Georges Beauchamps, Mohit Atul Kothare, Nanfei Zou, Ying Li, Lianfeng Huang, Daozhong Zou
-
Patent number: 9814714Abstract: The present disclosure provides methods of treating a subject suffering from or at risk of a BRAF V600 mutation or BRAF fusion mutation related disease or condition, without activating the MAPK pathway or inducing expression of MAPK pathway genes in cells harboring wild-type BRAF.Type: GrantFiled: May 20, 2016Date of Patent: November 14, 2017Assignee: Plexxikon Inc.Inventors: Prabha N. Ibrahim, Chao Zhang, Wayne Spevak, Jiazhong Zhang, Guoxian Wu, Jack Lin, Hanna Cho, Marika Nespi, Songyuan Shi, Todd Ewing, Ying Zhang, Gideon Bollag
-
Patent number: 9814715Abstract: Provided herein are novel compounds and pharmaceutically acceptable salts thereof that are liver X receptor modulators. Also provided are compositions comprising compounds of the invention and a carrier. Additionally, use of the compounds herein and methods for treating a disease or disorder associated with the liver X receptor are further described.Type: GrantFiled: June 15, 2016Date of Patent: November 14, 2017Assignee: Vitae Pharamceuticals, Inc.Inventors: Chengguo Dong, Yi Fan, Katerina Leftheris, Stephen D. Lotesta, Suresh B. Singh, Colin M. Tice, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Patent number: 9814716Abstract: Provided herein are compositions and methods for the treatment of autoimmune diseases, including lupus, uveitis and encephalitis. Said compositions useful for treating autoimmune diseases comprise pyrrolo-pyrazole PKC inhibitors.Type: GrantFiled: May 22, 2015Date of Patent: November 14, 2017Assignee: MINGSIGHT PHARMACEUTICALS, INC.Inventors: Michael Niesman, Kai Zhang
-
Patent number: 9814718Abstract: The present invention relates to compounds according to Formula (I): or a stereoisomer, tautomer or pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R4a, R4b, R5, R6, R7, R8, W1, W2, Y and n are as defined herein. Also described are pharmaceutically acceptable compositions of Formula I compounds as well as methods for utilizing the compounds of Formula I and the pharmaceutically acceptable compositions of Formula I compounds as inhibitors of Mnk as well as therapeutics for the treatment of diseases such as cancer.Type: GrantFiled: June 2, 2017Date of Patent: November 14, 2017Assignee: eFFECTOR THERAPEUTICS, INC.Inventors: Siegfried H. Reich, Paul A. Sprengeler, Stephen E. Webber, Alan X. Xiang, Justin T. Ernst
-
Patent number: 9814719Abstract: The present disclosure relates to chemical compounds, methods for their discovery, and their therapeutic and research use. In particular, the present disclosure provides compounds as therapeutic agents against bacterial infections (e.g., biofilms). The present disclosure also provides compounds as therapeutic agents in methods for treating pneumonia, methods for reducing bacterial virulence, methods for treating a bacterial wound infection, and methods for treating a urinary tract infection. The present disclosure also provides methods for treating a bacterial infection, wherein the bacterial infection has or is suspected of having an antibiotic-resistant bacteria. The present disclosure also provides surfaces coated with the chemical compounds disclosed herein.Type: GrantFiled: October 26, 2016Date of Patent: November 14, 2017Assignee: Curators of the University of MissouriInventors: Hongmin Sun, David W. Anderson, Lianhai Li
-
Patent number: 9814720Abstract: A method of inhibiting IL-17 expression in neutrophils of a subject in need thereof includes administering to neutrophils of the subject a therapeutically effective amount of agent that inhibits STAT3 mediated IL-17 expression in the neutrophils of the subject.Type: GrantFiled: August 27, 2015Date of Patent: November 14, 2017Assignee: Case Western Reserve UniversityInventor: Eric Pearlman
-
Patent number: 9814721Abstract: Disclosed herein are methods for treating a cancer comprising: a. administering a Btk inhibitor to a subject sufficient to result in an increase or appearance in the blood of a subpopulation of lymphocytes defined by immunophenotyping; b. determining the expression profile of one or more biomarkers from one or more subpopulation of lymphocytes; and c. administering a second agent based on the determined expression profile.Type: GrantFiled: March 10, 2016Date of Patent: November 14, 2017Assignee: Pharmacyclics LLCInventors: Joseph J. Buggy, Laurence Elias, Gwen Fyfe, Eric Hedrick, David J. Loury, Tarak D. Mody
-
Patent number: 9814722Abstract: The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.Type: GrantFiled: August 10, 2016Date of Patent: November 14, 2017Assignees: Incyte Holdings Corporation, Incyte CorporationInventors: James D. Rodgers, Stacey Shepard
-
Patent number: 9814723Abstract: Provided are articles of manufacture, compositions and methods for prophylaxis and/or therapy for disorders involving dizziness and/or vertigo. The articles of manufacture and compositions contain lamotrigen and/or bupropion. The compositions include pharmaceutical compositions which are intended to alleviate dizziness and/or vertigo. In certain aspects the disclosure includes articles of manufacture and kits which include printed material which provides an indication that the articles or compositions are intended to be used for prophylaxis and/or therapy of Meniere's Disease or a symptom thereof.Type: GrantFiled: June 4, 2015Date of Patent: November 14, 2017Inventor: Lixin Zhang
-
Patent number: 9814724Abstract: The present invention provides an antitumor effect potentiator for enhancing antitumor activity of an antitumor agent comprising tegafur in a therapeutically effective amount, gimeracil in an amount effective for enhancing an antitumor effect, and oteracil potassium in an amount effective for inhibiting a side effect. The antitumor effect potentiator comprising at least one member selected from the group consisting of folinic acid and pharmacologically acceptable salts thereof. The present invention also provides a method for enhancing an antitumor effect of an antitumor agent comprising the step of administering to a patient the aforementioned antitumor effect potentiator; a method for inhibiting the growth of a tumor comprising the step of administering to a patient the aforementioned antitumor effect potentiator and a method for cancer treatment comprising the step of administering to a patient the aforementioned antitumor agent.Type: GrantFiled: February 17, 2017Date of Patent: November 14, 2017Assignee: Taiho Pharmaceutical Co., Ltd.Inventors: Junji Uchida, Koyo Shudo
-
Patent number: 9814725Abstract: This invention generally relates to substituted imidazopyridine compounds, particularly substituted 4-(imidazo[1,2-a]pyridin-2-yl)benzamide compounds and salts thereof. This invention also relates to pharmaceutical compositions and kits comprising such a compound, uses of such a compound (including, for example, treatment methods and medicament preparations), processesor making such a compound, and intermediates used in such processes.Type: GrantFiled: February 2, 2017Date of Patent: November 14, 2017Assignee: NEOMED INSTITUTEInventors: Christophe Buon, Louis-David Cantin, Yun-Jin Hu, Xuehong Luo, Miroslaw Jerzy Tomaszewski
-
Patent number: 9814726Abstract: The present invention relates to a pharmaceutical composition for preventing or treating fatty liver diseases, containing (tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine or a pharmaceutically acceptable salt thereof as active ingredients. (Tetrahydropyran-4-yl)-[2-phenyl-5-(1,1-dioxo-thiomorpholin-4-yl)methyl-1H-indol-7-yl]amine or a pharmaceutically acceptable salt thereof, according to the present invention, can effectively inhibit fatty liver, hepatitis and hepatic fibrosis and can be useful for preventing or treating NAFLD, and in particular, NASH.Type: GrantFiled: April 17, 2015Date of Patent: November 14, 2017Assignee: LG CHEM, LTD.Inventors: Soon Ha Kim, Hyoung Jin Kim, Heui Sul Park, Seo Hyun Ahn, Min Ho Shong, Hyo Kyun Chung
-
Patent number: 9814727Abstract: The present invention relates to piperazine phenothiazine derivatives useful as therapeutic agents for treating spasticity, particularly following an ischemia or traumatic injury, or compression syndrome. The invention further relates to a pharmaceutical composition comprising a compound of the invention for treating spasticity.Type: GrantFiled: March 10, 2015Date of Patent: November 14, 2017Assignees: UNIVERSITE D'AIX-MARSEILLE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALEInventors: Pascale Boulenguez, Sylvie Liabeuf, Laëtitia Gourmand, Annelise Viallat-Lieutaud, Laurent Vinay
-
Patent number: 9814728Abstract: The use of BETi as a potential treatment for FSHD is provided. Specifically, the use of BETi, and particularly selective BETi for BRD4, are shown to inhibit DUX4 expression which is expected to result in a decrease in the severity of symptoms of FSHD. Further, the treatments are shown to work when pulsed as opposed to continuous. This allows for a BETi to be supplied to a human in a pulse, and then allows the human to not need any additional treatment for a window at least as long as the one of the treatment pulse.Type: GrantFiled: September 19, 2014Date of Patent: November 14, 2017Assignee: Saint Louis UniversityInventors: Francis M. Sverdrup, Stephen J. Tapscott
-
Patent number: 9814729Abstract: The present invention includes compositions that are useful in treating, ameliorating, or preventing nerve agent poisoning. The present invention also includes methods of preventing, treating or ameliorating nerve agent poisoning in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition of the invention. The present invention also includes methods of preventing, treating or ameliorating a seizure induced by a disease or disorder in a subject in need thereof, the method comprising administering to the subject an effective amount of a composition of the invention. The present invention also comprises a kit comprising compositions of the invention.Type: GrantFiled: March 14, 2013Date of Patent: November 14, 2017Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIAInventors: Jerome Niquet, Claude G. Wasterlain
-
Patent number: 9814730Abstract: A pharmaceutical composition for use as medicament that inhibits autocrine Human Chorionic Gonadotropin (HCG) production and thus carcinogenesis in adult human cells, the composition comprising at least a first pharmaceutically acceptable carrier and an active agent that is a competitively binding progesterone antagonist binding to steroid receptors of human cells, wherein the composition is provided in units designed for the monthly, semi-annual or annual application of the active agent in annual dosages in the range between 0.1 mg to 10.0 mg per kg of person/body-weight.Type: GrantFiled: February 2, 2017Date of Patent: November 14, 2017Assignee: FLAMINA HOLDING AGInventor: Michael May
-
Patent number: 9814731Abstract: In addition to its potent mechanism-dependent inhibition of estrogen biosynthesis, in accordance with the embodiments of the present invention, it has now been found that exemestane has novel chemoprotective properties which have hitherto not been explicitly recognized. The present invention provides methods for the use of compositions comprising exemestane for chemoprotection against a wide variety of non-mammary tumors (and possibly other chronic diseases) that are not estrogen-dependent, but have oxidative stress, inflammation and electrophile-damaging etiologies. The present invention also shows that exemestane shows powerful synergism with other classes of Nrf2-activators and phase 2 enzyme gene activators, including, for example sulforaphane (an isothiocyanate), shikonin (a naphthoquinone), zerumbone (a cyclic sesquiterpene) and resveratrol (a stilbene derivative), which increases the attractiveness of exemestane's novel uses.Type: GrantFiled: January 18, 2017Date of Patent: November 14, 2017Assignee: The Johns Hopkins UniversityInventors: Paul Talalay, Hua Liu
-
Patent number: 9814732Abstract: The invention relates to the use of ulipristal acetate, or any of its metabolites, in preventing or treating a breast tumor in a patient, preferably a patient that carries a mutation in BRCA1 gene.Type: GrantFiled: July 29, 2016Date of Patent: November 14, 2017Assignees: Laboratoire HRA-PHARMA, INSERM (Institut National de la Sante et de la Recherche Medicale)Inventors: Michele Resche-Rigon, Delphine Levy, Erin Gainer, Anne Gompel, Patricia Forgez, Laudine Desreumaux-Communal
-
Patent number: 9814733Abstract: In various embodiments, the present invention provides compositions comprising eicosapentaenoic acid or a derivative thereof and obeticholic acid or a derivative thereof. In other embodiments, the present invention provides methods of treating and/or preventing NASH and/or PBC comprising co-administering to a subject in need thereof eicosapentaenoic acid or a derivative thereof and obeticholic acid or a derivative thereof.Type: GrantFiled: December 31, 2013Date of Patent: November 14, 2017Assignee: A,arin Pharmaceuticals Ireland LimitedInventor: Joseph S. Zakrzewski
-
Patent number: 9814734Abstract: The present invention provides a bufalin liposome comprising a liposome bilayer and bufalin. The liposome bilayer comprises phospholipid, sterol and polyethylene glycol (PEG)-derived compound. The liposome of the present invention can be used to treat cancer, especially a cancer chosen from liver cancer, lung cancer, ovarian cancer, prostate cancer, colon cancer, pancreas cancer, gastric cancer, and leukemia. The preparation method of the present invention is simple, and the bufalin liposome can increase an effect of antitumor, reduce a toxicity compared with bufalin monomer, and has wide applications.Type: GrantFiled: March 29, 2013Date of Patent: November 14, 2017Assignee: The Fourth Military Medical UniversityInventors: Wei Cao, Siwang Wang, Ying Li, Yanhua Xie, Qian Yang
-
Patent number: 9814735Abstract: Chemical entities that are bufalin derivatives, pharmaceutical compositions and methods of treatment of cancer are described.Type: GrantFiled: June 20, 2016Date of Patent: November 14, 2017Assignee: SUZHOU NEUPHARMA CO., LTDInventor: Xiangping Qian
-
Patent number: 9814736Abstract: Disclosed are methods of administering 2-methylene-19-nor-(20S)-1?,25-dihydroxyvitamin D3 to treat and/or prevent secondary hyperparathyroidism and/or its accompanying symptoms in a subject having or at risk for developing secondary hyperparathyroidism, including a subject previously administered a calcimimetic.Type: GrantFiled: October 31, 2016Date of Patent: November 14, 2017Assignee: Wisconsin Alumni Research FoundationInventors: Hector F. DeLuca, Lori A. Plum, Margaret Clagett-Dame
-
Patent number: 9814737Abstract: An improved composition for skin cleansing and protection is disclosed. The composition contains an effective amount of at least one alpha-hydroxyl acid or a pharmaceutically acceptable salt thereof, at least one base, one surfactant and one skin protectant. Various additives and excipients may be included in the formulation. The improved composition disclosed herein achieves a higher bacteria killing rate and shows longer action duration. The disclosed composition is capable of penetrating deep into the skin which allows for delivery of more anti-microbials to sites that are at a higher risk of being infected. Various modifications of the improved composition are also disclosed.Type: GrantFiled: April 27, 2011Date of Patent: November 14, 2017Assignee: Mercy Medical Research InstituteInventors: Roger Huckfeldt, Phillip Finley
-
Patent number: 9814739Abstract: The present invention provides a compound of formula A: or a pharmaceutically acceptable salt thereof, wherein B, Q, R1, R5, R6, R7, R8 and Z are defined herein, which is a 2?-branched nucleoside useful for the treatment or prevention of viral infections, particularly dengue virus, yellow fever virus, West Nile virus, Japanese encephalitis virus, tick-borne encephalitis virus, Kunjin virus, Murray Valley encephalitis, St Louis encephalitis, Omsk hemorrhagic fever virus, bovine viral diarrhea virus, Zika virus and Hepatitis C virus.Type: GrantFiled: December 14, 2016Date of Patent: November 14, 2017Assignee: Novartis AGInventors: Sampath-Kumar Anandan, Virender Singh Aulakh, Martijn Fenaux, Xiaodong Lin, Liang Mao, Oliver Saunders, Zachary Kevin Sweeney, Fumiaki Yokokawa, Weidong Zhong
-
Patent number: 9814740Abstract: Methods of enhancing the effectiveness of an antibody-based therapeutic agent are provided herein. The methods include administering an antibody-based therapeutic and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells to a subject in need of such treatment. The subject may have cancer, an autoimmune disease, an infectious disease or an immunodeficiency. The composition capable of preferentially activating monocytes or macrophages may be a TLR3 agonist. The composition capable of preferentially depleting B10 cells may be a CD19 antibody. Pharmaceutical compositions comprising an antibody-based therapeutic agent and a composition capable of preferentially activating monocytes or macrophages or preferentially depleting B10 cells are also provided.Type: GrantFiled: December 21, 2011Date of Patent: November 14, 2017Assignee: Duke UniversityInventors: Thomas Tedder, Mayuka Horikawa
-
Patent number: 9814741Abstract: The invention provides, inter alia, methods for modulating DNA sensing pathways and the innate immune responses downstream of such pathways. The invention contemplates methods for down-regulating this pathway and/or the downstream innate immune response. The invention further contemplates methods for up-regulating this pathway and/or the downstream innate immune response.Type: GrantFiled: April 2, 2015Date of Patent: November 14, 2017Assignee: The General Hospital CorporationInventors: Mark Nackyoung Lee, Nir Hacohen
-
Patent number: 9814742Abstract: The present invention relates to a diet product comprising an alginate in an aqueous dissolved or swelled form at a pH value causing the alginate not to gel until after it is consumed and comes into contact gastric acid.Type: GrantFiled: July 21, 2014Date of Patent: November 14, 2017Assignee: S-Biotek AF 15. Marts 2006 1 APSInventor: Jens Steen Olsen
-
Patent number: 9814743Abstract: The present invention pertains generally to the field of therapy, and more specifically to the field of therapy for herpes simplex and herpes zoster, and more particularly, to methods of reducing the rate of relapse, delaying relapse, and/or preventing relapse of herpes labialis (cold sores on the lips), herpes genitalis (genital herpes), and herpes zoster (shingles, zona), by topical administration of polyethylene glycol (PEG), or a composition comprising PEG.Type: GrantFiled: July 8, 2011Date of Patent: November 14, 2017Assignee: DEVIREX AGInventors: Peter Vitins, Marcel Langenauer, Paul Martin Scherer
-
Patent number: 9814744Abstract: Provided herein are methods of making a cell growth scaffold from adipose tissue, cell growth scaffolds having low lipid content and methods of using the cell growth scaffold.Type: GrantFiled: December 20, 2010Date of Patent: November 14, 2017Assignee: University of Pittsburg—Of the Commonwealth System of Higher EducationInventors: Stephen F. Badylak, Bryan N. Brown, John M. Freund, J. Peter Rubin
-
Patent number: 9814745Abstract: The present application is directed to the field of implants comprising soft tissue for use in implantation in humans. The soft tissue implants of the present application are preferably obtained from xenograft sources. The present application provides a chemical process that sterilizes, removes antigens from and/or strengthens xenograft implants. The present techniques yield soft tissue implants having superior structural, mechanical, and/or biochemical integrity. The present application is also directed to processes for treating xenograft implants comprising soft tissues such as dermis, and to implants produced by such processes.Type: GrantFiled: March 14, 2013Date of Patent: November 14, 2017Assignee: TUTOGEN MEDICAL GMBHInventors: Arnd Wilhelmi, Silke Schreiner, Jake Michaelson, Steven Moore, Jennifer Faleris
-
Patent number: 9814746Abstract: Acellular amnion derived therapeutic compositions are described having a number of various compositional embodiments. An acellular amnion derived therapeutic composition has essentially no live or active amniotic cells. The amniotic cells may be destroyed, and the cells and cell debris may be removed from the acellular amnion derived therapeutic composition. An acellular amnion derived therapeutic composition may comprise micronized placental tissue particles, and/or amniotic fluid. An acellular amnion derived therapeutic composition may be a dispersion of micronized amniotic membrane combined with a fluid, such as plasma, saline, amniotic fluid, combinations thereof and the like. An acellular amnion derived therapeutic composition may be combined with a matrix component to form a composite. An acellular amnion derived therapeutic composition may be used in conjunction with a composition comprising viable cells, such as stem cells.Type: GrantFiled: September 14, 2015Date of Patent: November 14, 2017Assignee: Amnio Technology LLCInventors: Bruce Werber, Christian Beaudry, Terrell Suddarth
-
Patent number: 9814747Abstract: A therapeutic phenolic extract derived from plant biomass, and more specifically the indigenous Jamaican plant guaiacum officinale L. (Zygophyllaceae), for use in regressing or controlling HIV-1 replication in infected patients, and to help prevent sexual transmission of HIV-1, as well as the method for inhibiting HIV-1 by administering a pharmaceutically-acceptable amount of the crude extract to prevent HIV-viral replication without causing excessive damage to normal cells.Type: GrantFiled: July 21, 2015Date of Patent: November 14, 2017Inventors: Henry Lowe, Ngeh J. Toyang, Joseph Bryant
-
Patent number: 9814748Abstract: Provides is a salivation cocktail that comprises a food acid and a tingling sensate. The combination of a food acid and a tingling sensate has been found to synergistically increase salivation.Type: GrantFiled: April 3, 2013Date of Patent: November 14, 2017Assignee: TAKASAGO INTERNATIONAL CORPORATION (USA)Inventors: Charles Manley, David J. Spence, Carter B. Green
-
Patent number: 9814749Abstract: The present invention relates to a composition for preventing or treating dementia containing an extract of Prunus mume (Fructus Mume), and the Prunus mume extract of the present invention has outstanding effects in improving spatial recognition ability and in normalizing hippocampal damage (normalizing ERK phosphorylation, increasing ChAT and normalizing NF-kappa B) induced by chronic vascular brain damage in a vascular dementia animal model, and hence can be used to advantage as a medicinal product for preventing or treating dementia diseases and as a functional health food for preventing or alleviating dementia diseases that accompany vascular brain damage such as vascular dementia.Type: GrantFiled: October 4, 2011Date of Patent: November 14, 2017Assignee: Korea Institute of Oriental MedicineInventors: Won Kyung Jeon, Jung-Soo Han, Chang Hyun Han, Goya Choi
-
Patent number: 9814750Abstract: This invention relates to use of pharmaceutical compositions in preparing pharmaceuticals for treating diabetic ulcer in limb or on body surface, or in preparing medical dressing. The pharmaceutical compositions consist of (A) 3 to 15% by weight of edible beeswax and (B) 85 to 97% by weight of sesame oil extract of Huangqin, Huanglian, Huangbai, earthworm and poppy capsule, based on the total weight of the pharmaceutical compositions. In the sesame oil extract, each of Huangqin, Huanglian, Huangbai, earthworm and poppy capsule is in an amount of 2 to 10% by weight of dry raw material based on the total weight of sesame oil. This invention also relates to a medical dressing for treating diabetic ulcer and corresponding medicine box enclosing the said dressing.Type: GrantFiled: December 19, 2014Date of Patent: November 14, 2017Inventor: Rongxiang Xu
-
Patent number: 9814751Abstract: Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction.Type: GrantFiled: April 10, 2017Date of Patent: November 14, 2017Assignee: SILVERGATE PHARMACEUTICALS, INC.Inventors: Gerold L. Mosher, David W. Miles
-
Patent number: 9814752Abstract: This invention also provides a method to prevent, control, and treat a lipid metabolism disorder, a billary disorder, cardiovascular disease, obesity or an endocrine disorder by administering at least one agonist of guanalyte cyclase receptor either alone or in combination with a compound typically used to treat the disorder and or with an inhibitor of cGMP-dependent phosphodiesterases.Type: GrantFiled: June 17, 2015Date of Patent: November 14, 2017Assignee: SYNERGY PHARMACEUTICALS, INC.Inventor: Kunwar Shailubhai
-
Patent number: 9814753Abstract: The invention provides methods and compositions for use of desmopressin in combination with a beta-3-adrenergic receptor agonist. The methods and compositions are useful in the treatment of nocturia and other urinary frequency disorders.Type: GrantFiled: July 23, 2014Date of Patent: November 14, 2017Assignee: Serenity Pharmaceuticals LLCInventors: Seymour H. Fein, Samuel Herschkowitz
-
Patent number: 9814754Abstract: A novel combination comprising a ?-hairpin peptidomimetic of the formula cyclo(-Thr-Trp-Ile-Dab-Orn-DDab-Dab-Trp-Dab-Dab-Ala-Ser-DPro-Pro) (I), and a further compound with antibiotic activity, that enable therapeutic control of specific bacterial infections in human or animals at doses of the individual compounds lower than either of the compounds administered alone. The combination can be used as a medicament to treat e.g. skin or soft tissue infections; eye, ear, blood stream, or intra-abdominal infections; infections related to respiratory diseases, to bone diseases, to cardiovascular diseases, to genitourinal diseases, or to gastrointestinal diseases.Type: GrantFiled: August 7, 2013Date of Patent: November 14, 2017Assignee: Polyphor AGInventors: Glenn E. Dale, Daniel Obrecht, Francesca Bernardini